Table of Content

1. Key Insights


2. Report Introduction


3. Traumatic Brain Injury Market Overview at a Glance

3.1. Market Share (%) Distribution of Traumatic Brain Injury in 2018

3.2. Market Share (%) Distribution of Traumatic Brain Injury in 2030


4. Executive Summary of Traumatic Brain Injury


5. Disease Background and Overview

5.1. Introduction

5.2. Symptoms

5.3. Etiology

5.4. Pathophysiology

5.4.1. Primary Brain Injuries

5.4.2. Secondary Brain Injuries

5.5. Neurodegenerative conditions associated with TBI

5.6. Diagnosis

5.6.1. CDC Diagnosis Guidelines

5.7. Biomarkers


6. Management and Treatment of TBI

6.1.1. CDC Treatment Guidelines

6.1.2. Guidelines by Brain Trauma Foundation


7. Epidemiology and Patient Population

7.1. Key Findings

7.2. 7MM Total Incident Patient Population of Traumatic Brain Injury

7.3. Epidemiology of Traumatic Brain Injury

7.4. The United States

7.4.1. Incident Cases of Traumatic Brain Injury in the United States

7.4.2. Severity-specific Cases of Traumatic Brain Injury in the United States

7.4.3. Gender-specific Incidence of Traumatic Brain Injury in the United States

7.4.4. Incidence of Traumatic Brain Injury by Age Group in the United States

7.5. EU5

7.5.1. Germany

7.5.2. France

7.5.3. Italy

7.5.4. Spain

7.5.5. United Kingdom

7.6. Japan

7.6.1. Incident Cases of Traumatic Brain Injury in Japan

7.6.2. Severity-specific Cases of Traumatic Brain Injury in Japan

7.6.3. Gender-specific Incidence of Traumatic Brain Injury in Japan

7.6.4. Incidence of Traumatic Brain Injury by Age Group in Japan


8. Organizations contributing to Traumatic Brain Injury


9. Patient Journey


10. Case Reports


11. Emerging Therapies

11.1.VAS203: Vasopharm

11.1.1. Drug Description

11.1.2. Regulatory Milestones

11.1.3. Clinical Development

11.1.4. Clinical Trials Information

11.1.5. Safety and Efficacy

11.1.6. Product Profile

11.2.NeuroSTAT: NeuroVive Pharmaceutical

11.2.1. Drug Description

11.2.2. Regulatory Milestones

11.2.3. Clinical Development

11.2.4. Clinical Trials Information

11.2.5. Safety and Efficacy

11.2.6. Product Profile

11.3.CEVA101: Cellvataion

11.3.1. Drug Description

11.3.2. Regulatory Milestones

11.3.3. Clinical Development

11.3.4. Clinical Trials Information

11.3.5. Safety and Efficacy

11.3.6. Product Profile


12. Traumatic Brain Injury: Seven Major Market Analysis

12.1.Key Findings

12.2.Market Size of Traumatic Brain Injury in 7MM

12.3.Market Size of Traumatic Brain Injury by Therapies

12.4.Market Outlook

12.5.United States Market Size

12.5.1. Total Market Size of Traumatic Brain Injury in the United States

12.5.2. Market Size of Traumatic Brain Injury by Therapies in the United States

12.6.EU-5 Market Size

12.6.1. Germany

12.6.2. France

12.6.3. Italy

12.6.4. Spain

12.6.5. United Kingdom

12.7.Japan

12.7.1. Total Market size of Traumatic Brain Injury in Japan

12.7.2. Market Size of Traumatic Brain Injury by Therapies in Japan


13. KOL Views


14. Market Access


15. Market Drivers


16. Market Barriers


17. SWOT Analysis


18. Unmet Needs


19. Appendix

19.1.Bibliography

19.2.Report Methodology


20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight



List of Figures


Figure 1: Different phases of traumatic brain injury (TBI) pathophysiology and relative immune response

Figure 2: Schematic representation of pathophysiology of traumatic brain injury (TBI)

Figure 3: Multi-modality monitor in neurocritical care?illustrating cerebral microdialysis, intracranial pressure and brain tissue oxygenation monitoring

Figure 4: Decompressive Craniectomy

Figure 5: Incident Population of Traumatic Brain Injury in 7MM (2018–2030)

Figure 6: Incident Cases of Traumatic Brain Injury in the United States (2018–2030)

Figure 7: Severity-specific Cases of Traumatic Brain Injury in the United States (2018–2030)

Figure 8: Gender-specific Incidence of Traumatic Brain Injury in the United States (2018–2030)

Figure 9: Incidence of Traumatic Brain Injury by Age Group in the United States (2018–2030)

Figure 10: Incident Cases of Traumatic Brain Injury in Germany (2018–2030)

Figure 11: Severity-specific cases of Traumatic Brain Injury in Germany (2018–2030)

Figure 12: Gender-specific Incidence of Traumatic Brain Injury in Germany (2018–2030)

Figure 13: Incidence of Traumatic Brain Injury by Age group in Germany (2018–2030)

Figure 14: Incident Cases of Traumatic Brain Injury in France (2018–2030)

Figure 15: Severity-specific Cases of Traumatic Brain Injury in France (2018–2030)

Figure 16: Gender-specific Incidence of Traumatic Brain Injury in France (2018–2030)

Figure 17: Incidence of Traumatic Brain Injury by Age Group in France (2018–2030)

Figure 18: Incident Cases of Traumatic Brain Injury in Italy (2018–2030)

Figure 19: Severity-specific of Traumatic Brain Injury in Italy (2018–2030)

Figure 20: Gender-specific Incidence of Traumatic Brain Injury in Italy (2018–2030)

Figure 21: Incidence of Traumatic Brain Injury by Age Group in Italy (2018–2030)

Figure 22: Incident Cases of Traumatic Brain Injury in Spain (2018–2030)

Figure 23: Severity-Specific cases of Traumatic Brain Injury in Spain (2018–2030)

Figure 24: Gender-specific Incidence of Traumatic Brain Injury in Spain (2018–2030)

Figure 25: Incidence of Traumatic Brain Injury by Age Group in Spain (2018–2030)

Figure 26: Incident Cases of Traumatic Brain Injury in the United Kingdom (2018–2030)

Figure 27: Severity-specific Cases of Traumatic Brain Injury in the United Kingdom (2018–2030)

Figure 28: Gender-specific Incidence of Traumatic Brain Injury in the United Kingdom (2018–2030)

Figure 29: Incidence of Traumatic Brain Injury by Age Group in the United Kingdom (2018–2030)

Figure 30: Incident Cases of Traumatic Brain Injury in Japan (2018–2030)

Figure 31: Severity-specific of Traumatic Brain Injury in Japan (2018–2030)

Figure 32: Gender-specific Incidence of Traumatic Brain Injury in Japan (2018–2030)

Figure 33: Incidence of Traumatic Brain Injury by Age Group in Japan (2018–2030)

Figure 34: Seven Major Market Size of Traumatic Brain Injury in USD Million (2018–2030)

Figure 35: Seven Major Market Size of Traumatic Brain Injury by Therapies in USD Million (2018–2030)

Figure 36: Market Size of Traumatic Brain Injury in the United States, USD Million (2018–2030)

Figure 37: The United States Market Size of Traumatic Brain Injury by Therapies in USD Million

Figure 38: Market Size of Traumatic Brain Injury in Germany, USD Million (2018–2030)

Figure 39: The Germany Market Size of Traumatic Brain Injury by Therapies in USD Million

Figure 40: Market Size of Traumatic Brain Injury in France, USD Million (2018–2030)

Figure 41: The France Market Size of Traumatic Brain Injury by Therapies in USD Million

Figure 42: Market Size of Traumatic Brain Injury in Italy, USD Million (2018–2030)

Figure 43: The Italy Market Size of Traumatic Brain Injury by Therapies in USD Million

Figure 44: Market Size of Traumatic Brain Injury in Spain, USD Million (2018–2030)

Figure 45: The Spain Market Size of Traumatic Brain Injury by Therapies in USD Million

Figure 46: Market Size of Traumatic Brain Injury in the United Kingdom, USD Million (2018–2030)

Figure 47: The United Kingdom Market Size of Traumatic Brain Injury by Therapies in USD Million

Figure 48: Market Size of Traumatic Brain Injury in Japan, USD Million (2018–2030)

Figure 49:The Japan Market Size of Traumatic Brain Injury by Therapies in USD Million (2018–2030)


List of Tables


Table 1: Summary of? Traumatic Brain Injury, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Criteria for Inclusion and exclusion

Table 3: Four Critical Questions

Table 4: Updated Treatment Recommendations

Table 5: Diagnosed Incident Patient Population of Traumatic Brain Injury in 7MM (2018–2030)

Table 6: Incident Cases of Traumatic Brain Injury in the United States (2018–2030)

Table 7: Severity-specific Cases of Traumatic Brain Injury in the United States (2018–2030)

Table 8: Gender-specific Incidence of Traumatic Brain Injury in the United States (2018–2030)

Table 9: Incidence of Traumatic Brain Injury by Age Group in the United States (2018–2030)

Table 10: Incident Cases of Traumatic Brain Injury in Germany (2018–2030)

Table 11: Severity-specific cases of Traumatic Brain Injury in Germany (2018–2030)

Table 12: Gender-specific Incidence of Traumatic Brain Injury in Germany (2018–2030)

Table 13: Incidence of Traumatic Brain Injury by Age group in Germany (2018–2030)

Table 14: Incident Cases of Traumatic Brain Injury in France (2018–2030)

Table 15: Severity-specific cases of Traumatic Brain Injury in France (2018–2030)

Table 16: Gender-specific Incidence of Traumatic Brain Injury in France (2018–2030)

Table 17: Incidence of Traumatic Brain Injury by Age Group in France (2018–2030)

Table 18: Incident Cases of Traumatic Brain Injury in Italy (2018–2030)

Table 19: Severity-specific of Traumatic Brain Injury in Italy (2018–2030)

Table 20: Gender-specific Incidence of Traumatic Brain Injury in Italy (2018–2030)

Table 21: Incidence of Traumatic Brain Injury by Age Group in Italy (2018–2030)

Table 22: Incident Cases of Traumatic Brain Injury in Spain (2018–2030)

Table 23: Severity-specific of Traumatic Brain Injury in Spain (2018–2030)

Table 24: Gender-specific Incidence of Traumatic Brain Injury in Spain (2018–2030)

Table 25: Incidence of Traumatic Brain Injury by Age Group in Spain (2018–2030)

Table 26: Incident Cases of Traumatic Brain Injury in the United Kingdom (2018–2030)

Table 27: Severity-specific cases of Traumatic Brain Injury in the United Kingdom (2018–2030)

Table 28: Gender-specific Incidence of Traumatic Brain Injury in the United Kingdom (2018–2030)

Table 29: Incidence of Traumatic Brain Injury by Age Group in the United Kingdom (2018–2030)

Table 30: Incident Cases of Traumatic Brain Injury in Japan (2018–2030)

Table 31: Severity-specific Cases of Traumatic Brain Injury in Japan (2018–2030)

Table 32: Gender-specific Incidence of Traumatic Brain Injury in Japan (2018–2030)

Table 33: Incidence of Traumatic Brain Injury by Age Group in Japan (2018–2030)

Table 34: Organizations contributing to Traumatic Brain Injury

Table 35: VAS203, Clinical Trial Description, 2021

Table 36: NeuroSTAT, Clinical Trial Description, 2021

Table 37: CEVA101, Clinical Trial Description, 2021

Table 38: 7 Major Market Size of Traumatic Brain Injury in USD Million (2018–2030)

Table 39:? Seven Major Market Size of Traumatic Brain Injury by Therapies in USD Million (2018–2030)

Table 40: United States Market Size of Traumatic Brain Injury in USD Million (2018–2030)

Table 41:? United States Market Size of Traumatic Brain Injury by Therapies in USD Million (2018–2030)

Table 42: Germany Market Size of Traumatic Brain Injury in USD Million (2018–2030)

Table 43:? Germany Market Size of Traumatic Brain Injury by Therapies in USD Million (2018–2030)

Table 44: France Market Size of Traumatic Brain Injury in USD Million (2018–2030)

Table 45:? France Market Size of Traumatic Brain Injury by Therapies in USD Million (2018–2030)

Table 46: Italy Market Size of Traumatic Brain Injury in USD Million (2018–2030)

Table 47:? Italy Market Size of Traumatic Brain Injury by Therapies in USD Million (2018–2030)

Table 48: Spain Market Size of Traumatic Brain Injury in USD Million (2018–2030)

Table 49:? Spain Market Size of Traumatic Brain Injury by Therapies in USD Million (2018–2030)

Table 50: United Kingdom Market Size of Traumatic Brain Injury in USD Million (2018–2030)

Table 51:? United Kingdom Market Size of Traumatic Brain Injury by Therapies in USD Million (2018–2030)

Table 52: Japan Market Size of Traumatic Brain Injury in USD Million (2018–2030)

Table 53: Japan Market Size of Traumatic Brain Injury by Therapies in USD Million (2018–2030)